Murakami Kaoru, Pagano Ian, Chen Runpu, Sun Yijun, Goodison Steve, Rosser Charles J, Furuya Hideki
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Diagnostics (Basel). 2021 Jun 3;11(6):1023. doi: 10.3390/diagnostics11061023.
The Oncuria™ urine test for the detection of bladder cancer measures a multiplex protein signature. In this study, we investigated the influence of urinary cellularity, protein, and hematuria on the performance of the Oncuria™ test in an ex vivo experimental model.
Pooled urine from healthy subjects was spiked with cultured benign (UROtsa) or malignant cells (T24), cellular proteins, or whole blood. The resulting samples were analyzed using the Oncuria™ test following the manufacturer's instructions.
Urine samples obtained from healthy subjects were negative for bladder cancer by Oncuria™ test criteria. The majority of the manipulated conditions did not result in a false-positive test. The addition of whole blood (high concentration) did result in a false-positive result, but this was abrogated by sample centrifugation prior to analysis. The addition of cellular proteins (high concentration) resulted in a positive Oncuria™ test, and this was unaffected by pre-analysis sample centrifugation.
The Oncuria™ multiplex test performed well in the ex vivo experimental model and shows promise for clinical application. The identification of patients who require additional clinical evaluation could reduce the need to subject patients who do not have bladder cancer to frequent, uncomfortable and expensive cystoscopic examinations, thus benefiting both patients and the healthcare system.
用于检测膀胱癌的Oncuria™尿液检测可测量多种蛋白质特征。在本研究中,我们在体外实验模型中研究了尿细胞成分、蛋白质和血尿对Oncuria™检测性能的影响。
将来自健康受试者的混合尿液加入培养的良性(UROtsa)或恶性细胞(T24)、细胞蛋白质或全血。按照制造商的说明,使用Oncuria™检测对所得样本进行分析。
根据Oncuria™检测标准,来自健康受试者的尿液样本对膀胱癌呈阴性。大多数操作条件未导致假阳性检测结果。加入全血(高浓度)确实导致了假阳性结果,但在分析前通过样本离心消除了这一结果。加入细胞蛋白质(高浓度)导致Oncuria™检测呈阳性,且这不受分析前样本离心的影响。
Oncuria™多重检测在体外实验模型中表现良好,具有临床应用前景。识别需要额外临床评估的患者可以减少对没有膀胱癌的患者进行频繁、不适且昂贵的膀胱镜检查的需求,从而使患者和医疗系统都受益。